8 tulemused
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to the field of cancer diagnostics and therapeutics. In particular it relates to a gene which appears to be significantly associated with the progression of cancer to more advanced stages, including metastasis.
2. Background
FIELD OF THE INVENTION
This invention relates to a method for activation of T cell protein tyrosine phosphatase (TCPTP) and a method for inhibiting tyrosine kinase signalling in an individual. Further, the invention concerns a method for preventing or treating a disease or disorder in an individual,
BACKGROUND OF THE INVENTION
Pleiotrophin (PTN) is a platelet-derived growth factor-inducible heparin-binding growth and differentiation factor that signals diverse phenotypes in normal and deregulated cellular growth and differentiation. See Milner, et al., (1989) Biochem. Biophys. Res. Commun. 165,
BACKGROUND
The molecular pathways involved in proliferative disorders and oncogenesis often represent aberrations of processes that normally occur during embryogenesis. One such pathway implicated in proliferative disorders such as cancer is the evolutionally conserved gene network termed the
TECHNICAL FIELD
The present disclosure relates generally to methods of treating a subject having a prostate cancer bone metastasis. The present disclosure also relates to methods of prophylactically treating a subject at risk of developing a prostate cancer bone metastasis. In particular, the
TECHNICAL FIELD
The present invention relates to a crystal structure of PRL-1 protein and a method of crystallization thereof, more precisely, a method of crystallization of PRL-1 protein including the steps of mass-expressing human originated PRL-1 protein in E-coli transformant and purifying those
The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formulae (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated
TECHNICAL FIELD
This invention generally relates to biochemistry, medicine and drug discovery. In particular, in alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or Slingshot-2 (SlingSHot-2), a phosphatase enzyme that regulates actin filaments, and